23,584 Shares in Becton Dickinson and Co (BDX) Acquired by Kavar Capital Partners LLC
Kavar Capital Partners LLC bought a new stake in Becton Dickinson and Co (NYSE:BDX) in the 3rd quarter, HoldingsChannel reports. The institutional investor bought 23,584 shares of the medical instruments supplier’s stock, valued at approximately $6,155,000. Becton Dickinson and comprises approximately 3.0% of Kavar Capital Partners LLC’s holdings, making the stock its 4th largest position.
Several other hedge funds have also added to or reduced their stakes in BDX. Fundsmith Equity Fund L.P. bought a new position in Becton Dickinson and during the second quarter valued at $894,775,000. Hudson Bay Capital Management LP grew its holdings in Becton Dickinson and by 119.9% during the second quarter. Hudson Bay Capital Management LP now owns 166,094 shares of the medical instruments supplier’s stock valued at $39,789,000 after purchasing an additional 90,564 shares during the period. Kiwi Wealth Investments Limited Partnership bought a new position in Becton Dickinson and during the second quarter valued at $9,161,000. FMR LLC grew its holdings in Becton Dickinson and by 7.6% during the second quarter. FMR LLC now owns 16,067,452 shares of the medical instruments supplier’s stock valued at $3,849,118,000 after purchasing an additional 1,129,688 shares during the period. Finally, Parsons Capital Management Inc. RI grew its holdings in Becton Dickinson and by 3.5% during the second quarter. Parsons Capital Management Inc. RI now owns 7,262 shares of the medical instruments supplier’s stock valued at $1,740,000 after purchasing an additional 246 shares during the period. 86.25% of the stock is owned by institutional investors.
NYSE:BDX opened at $243.40 on Tuesday. The firm has a market cap of $65.84 billion, a price-to-earnings ratio of 22.11, a P/E/G ratio of 1.69 and a beta of 1.19. Becton Dickinson and Co has a 1 year low of $209.91 and a 1 year high of $265.87. The company has a current ratio of 1.23, a quick ratio of 0.81 and a debt-to-equity ratio of 0.95.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 31st. Investors of record on Monday, December 10th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.27%. This is an increase from Becton Dickinson and’s previous quarterly dividend of $0.75. Becton Dickinson and’s dividend payout ratio (DPR) is 27.25%.
In related news, CEO Vincent A. Forlenza sold 16,866 shares of the stock in a transaction on Tuesday, November 13th. The stock was sold at an average price of $237.61, for a total value of $4,007,530.26. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Charles R. Bodner sold 2,080 shares of the stock in a transaction on Friday, November 16th. The stock was sold at an average price of $245.83, for a total value of $511,326.40. Following the completion of the sale, the senior vice president now owns 4,497 shares in the company, valued at approximately $1,105,497.51. The disclosure for this sale can be found here. Insiders sold 75,908 shares of company stock worth $18,085,616 in the last quarter. 1.00% of the stock is currently owned by company insiders.
Several equities analysts have weighed in on BDX shares. KeyCorp increased their price objective on Becton Dickinson and from $264.00 to $273.00 and gave the company an “overweight” rating in a report on Thursday, November 8th. Wells Fargo & Co increased their target price on Becton Dickinson and from $275.00 to $290.00 and gave the stock an “outperform” rating in a research report on Thursday, September 6th. They noted that the move was a valuation call. Citigroup dropped their target price on Becton Dickinson and from $289.00 to $279.00 and set a “buy” rating on the stock in a research report on Tuesday, November 13th. Barclays began coverage on Becton Dickinson and in a research report on Monday, October 15th. They set an “equal weight” rating and a $278.00 target price on the stock. Finally, Morgan Stanley increased their target price on Becton Dickinson and from $250.00 to $280.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 4th. Five investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Becton Dickinson and has an average rating of “Buy” and an average target price of $253.79.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Further Reading: What is a bull market?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.